Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

Guillermo De Velasco1,2, Youjin Je3, Dominick Bossé1, Mark M. Awad1, Patrick A. Ott1, Raphael B. Moreira1, Fabio Schutz4, Joaquim Bellmunt1, Guru P. Sonpavde5, F. Stephen Hodi1, and Tony K. Choueiri1

Abstract

Immune-related adverse events (irAE) have been described with immune checkpoint inhibitors (ICI), but the incidence and relative risk (RR) of irAEs associated with these drugs remains unclear. We selected five key irAEs from treatments with approved cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), programmed cell death 1 (PD-1), and programmed death ligand 1 (PD-L1) inhibitors (ipilimumab, nivolumab, or pembrolizumab, and atezolizumab, respectively) to better characterize their safety profile. We performed a meta-analysis of randomized phase II/III immunotherapy trials, with non-ICI control arms, conducted between 1996 and 2016. We calculated the incidence and RR of selected all-grade and high-grade gastrointestinal, liver, skin, endocrine, and pulmonary irAEs across the trials using random-effect models. Twenty-one trials were included, totaling 11,454 patients, of whom 6,528 received an ICI (nivolumab, 1,534; pembrolizumab, 1,522; atezolizumab, 751; and ipilimumab, 2,721) and 4,926 had not. Compared with non-ICI arms, ICIs were associated with more all-grade colitis (RR 7.66, P < 0.001), aspartate aminotransferase (AST) elevation (RR 1.80; P = 0.020), rash (RR 2.50; P = 0.001), hypothyroidism (RR 6.81; P < 0.001), and pneumonitis (RR 4.14; P = 0.012). Rates of high-grade colitis (RR 8.55; P < 0.001) and AST elevation (RR 2.79; P = 0.014) were higher in the ICI arms. Ipilimumab was associated with a higher risk of all-grade rash (P = 0.006) and high-grade colitis (P = 0.021) compared with PD-1/PD-L1 ICIs. Incidence of fatal irAE was <1%. This meta-analysis offers substantial evidence that ICIs are associated with a small but significant increase in risk of selected all-grade irAEs and high-grade gastrointestinal and liver toxicities. Although fatal irAEs remain rare, AEs should be recognized promptly as early interventions may alleviate future complications.

Introduction

Immune checkpoint inhibitors (ICI) have already been approved for use in melanoma, non–small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, and squamous cell carcinoma of the head and neck (SCCHN; Supplementary Table S1), with likely more approvals coming for an increasing number of tumors types in the near future. Indeed, these novel immune-modulating molecules have resulted in major advances in the treatment of these tumors and they have shown promising activity against many other tumor types such as Merkel-cell carcinoma, Hodgkin lymphoma, and mismatch repair–deficient tumors (1–5).

Ipilimumab was the first inhibitor of cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) approved by the FDA, whereas nivolumab and pembrolizumab were the first two programmed death 1 inhibitors to be approved (6). Atezolizumab is the first programmed death ligand 1 (PD-L1) inhibitor approved by the FDA (7). These drugs are also being assessed in many different solid and hematologic malignancies, including registration trials enrolling thousands of patients. Compared with cytotoxic or targeted agents, ICIs have a distinct toxicity profile (8). They can induce infiltration of immune cells into normal tissues, which leads to autoimmune-like toxicities different than traditional chemotherapy or targeted therapies (9, 10). Almost every organ may be affected with immune-related adverse events (irAE), including the skin, bowels, liver, kidneys, eyes, endocrine tissues, and even the central nervous system (11). Dermatological and gastrointestinal events are the most commonly reported irAEs (8, 10, 11), whereas less common toxicities include endocrine, hepatic, and neurological events (12, 13). A pooled analysis of nearly 1,500 patients with melanoma treated with ipilimumab showed that the incidence of irAEs could be as high as 65% (14, 15). Although infrequent, severe and even life-threatening irAEs such as immune-related pneumonitis and colitis may occur with these drugs (16, 17). In this report, we conducted a systematic review and meta-analysis to investigate the safety...
profiles of ipilimumab, nivolumab, pembrolizumab, and atezolizumab, and identify the incidence and relative risk (RR) of five irAEs of interest.

**Patients and Methods**

**Literature search and inclusion criteria**

We identified all randomized clinical trials that compared ipilimumab (Yervoy), nivolumab (Opdivo), pembrolizumab (Keytruda), or atezolizumab (Tecentriq) with a nonimmunotherapy control arm. An independent review of PubMed and Embase from January 1, 1996, to December 15, 2016, was conducted. Keywords included in the search were “ipilimumab,” “nivolumab,” “pembrolizumab,” “atezolizumab,” and studies were limited to randomized controlled trials in humans and published in English. Abstract proceedings and virtual meeting presentations containing the same terms from the American Society of Clinical Oncology and the European Society of Medical Oncology conferences held between January 2010 and December 15, 2016, were also used to identify relevant clinical trials. We reviewed each publication, and only the most recent or complete report of clinical trials was included when duplicate publications were identified. On December 15, 2016, the online updated manufacturers’ package inserts of ipilimumab, nivolumab, pembrolizumab, and atezolizumab were also reviewed to identify relevant information not previously reported in published clinical trials. No placebo-controlled randomized trials including pembrolizumab, nivolumab, or atezolizumab were found. Selected all-grade and high-grade (grade 3 or higher) irAEs included gastrointestinal, liver, skin, endocrine, and pulmonary toxicities. Colitis was the most relevant gastrointestinal irAE; rash the most relevant for dermatologic irAEs; increases in aspartate aminotransferase (AST) for hepatic irAEs; hypothyroidism for thyroid/endocrine irAEs, and pneumonitis for lung-related irAEs. Trials that met the following criteria were included in the meta-analysis: randomized phase II and III trials, prospective clinical trials in patients with cancer, and trials that had safety data available, including irAEs. Three reviewers (G. De Velasco, D. Bossé, T.K. Choueiri) independently evaluated studies for eligibility.

**Data extraction and clinical end points**

Data abstraction was conducted independently by two investigators (G. De Velasco, D. Bossé, T.K. Choueiri) according to the Quality of Reporting of Meta-Analyses (QUORUM) guidelines and any discrepancies between reviewers were resolved by consensus (G. De Velasco, D. Bossé, T.K. Choueiri). For each study, the following information was extracted: first author’s last name, year of publication, phase of the trial, number of enrolled subjects, number of patients included in the safety analysis, treatment arms, number of patients in the ICI treatment and control groups, type of underlying malignancy, median age, overall survival, adverse events of interest, and the name of the ICI (ipilimumab, nivolumab, pembrolizumab, or atezolizumab).

**Statistical analysis**

All statistical analyses were performed using Stata/SE software, version 12.0 (Stata-Corp LP). For the calculation of incidence, the number of irAEs and the number of patients receiving ipilimumab, nivolumab, pembrolizumab, and atezolizumab were extracted from the safety profile. The proportion of patients with those adverse outcomes and 95% CIs were derived for each study. The control arm was used as comparative arm to calculate the RRs of irAEs in patients assigned to ipilimumab, nivolumab, pembrolizumab, or atezolizumab versus controls in the same trial. For trials reporting zero events in the ICI treatment or the control group, we applied a classic half-integer continuity correction to compute the RRs and variances.

To calculate the overall incidence and RRs of immune-related toxicities, we combined trial-specific estimates using random-effects models with the method of DerSimonian and Laird, which considers both within-study and between-study variations (18). Statistical heterogeneity among studies included in the meta-analysis was assessed using Cochrane Q statistic, and the inconsistency was quantified with the I² statistic, which is used to describe the percentage of total variation across studies that is due to heterogeneity rather than chance; a value of 0% indicates no observed heterogeneity, whereas values between 0% and 100% show increasing heterogeneity. The assumption of homogeneity was considered invalid for P values < 0.10. To explore the possible reasons for the heterogeneity, we conducted subgroup analyses by underlying malignancy or ICI, phase of clinical trial, age, and publication year, and we tested for variation in risk estimates by those variables through meta-regression analyses. Finally, potential publication bias was evaluated through Begg funnel plots to examine relative symmetry of individual study estimates around the overall estimate (19, 20). A two-tailed P value of < 0.05 was considered statistically significant.

**Results**

**Characteristics of trials, patients, and interventions**

Our search yielded a total of 1,617 potentially relevant studies with ipilimumab, nivolumab, pembrolizumab, or atezolizumab. After matching studies from different sources, we obtained 361 definitive studies after going through our selection process for the randomized controlled clinical trials (Fig. 1). Initially, 265 studies were excluded for at least one of the following reasons: reviews, letters, editorials, biomarkers only, cases retrospective studies, or commentaries. We screened 96 publications and 65 clinical trials were excluded (5 expanded-access studies with no control arm and 60 early-phase I/II or nonrandomized clinical trials). After reviewing the remaining 31 publications, 21 trials met the criteria for final inclusion in the meta-analysis (randomized phase II and III trials with a control arm that does not contain an ICI). Baseline characteristics of each trial are presented in Table 1. Eight trials were performed in patients with non–small cell lung cancer, six in melanoma, two in small cell lung cancer, two in prostate cancer and one in renal cell carcinoma, bladder cancer, and squamous cell cancer of the head and neck. Sixteen trials had two arms and five trials had three arms. A total of 11,454 patients were available for the meta-analysis: 6,528 patients were assigned to ICI arms (ipilimumab 2,721, nivolumab 1,534, pembrolizumab 1,522, and atezolizumab 751 patients), and 4,926 were assigned to placebo or control arms [placebo 1,069, chemotherapy 3,328, and biologic agents 529 (including everolimus and glycoprotein 100)]. All randomized controlled trials were sponsored by pharmaceutical companies and involved solid tumors. None of these studies had toxicity as a primary endpoint. The evaluation of the irAEs was based on the Common Terminology Criteria for Adverse Events version 3.0 or 4.0. The grading of rashes was the main variation between the two versions (Supplementary Table S2).
Incidence and relative risk of all-grade irAEs of interest

In patients receiving ICI, all-grade colitis occurred in 206 of 5,422 (2.3%), AST elevation in 330 of 3,855 (6.5%), rash in 952 of 5,777 (13.9%), hypothyroidism in 244 of 4,622 (5.1%), and pneumonitis in 119 of 4,599 (2.6%; Table 2). Compared with patients in the non-ICI arms, those treated with an ICI were at a higher risk of immune-related colitis [RR 7.66; 95% confidence interval (CI), 4.58–12.8; P < 0.001], AST elevation (RR 1.80; 95% CI, 1.10–2.96; P = 0.020), rash (RR 2.50; 95% CI, 1.65–3.78; P = 0.001), hypothyroidism (RR 6.81; 95% CI, 4.20–11.0; P < 0.001), and pneumonitis (RR 4.14, 95% CI, 1.37–12.5; P = 0.012; Table 3).

Incidence and relative risk of high-grade irAEs of interest

In patients receiving ICI, high-grade colitis occurred in 119 of 5,442 (1.5%) patients, AST elevation in 94 of 3,855 (1.5%) patients, rash in 50 of 5,299 (1.1%) patients, hypothyroidism in 5 of 4,144 (0.3%), and pneumonitis in 42 of 4,599 (1.1%) patients receiving ICI (Table 2). Compared with patients in the non-ICI arms, those treated with an ICI were at a higher risk for high-grade colitis (RR 5.85; 95% CI, 2.66–12.8; P < 0.001), and increased AST (RR 2.79; 95% CI, 1.23–6.32; P = 0.014). The incidence of high-grade rash, hypothyroidism, or pneumonitis in patients who received ICIs was no different from patients in the non-ICI arms (Table 3). However, after excluding the CheckMate-
In which the comparator arm was everolimus, a drug known to cause pneumonitis, the risk of high-grade pneumonitis was significantly higher than the non-ICI group (RR 2.99; 95% CI, 1.37 to 6.54; P = 0.006). We found some heterogeneity for the RRs of all-grade AST elevation ($I^2 = 78.7\%$), rash ($I^2 = 86.1\%$), and pneumonitis ($I^2 = 78.9\%$), but not for the other toxicities. Overall, the Beg test detected no evidence of publication bias, except for colitis.

### Subgroup analyses

Ipiilimumab, compared with the PD-1/PD-L1 inhibitors, had a higher risk for all-grade immune-related rash [(RR 3.94; 95% CI, 3.02–5.14) vs. (RR 1.59; 95% CI, 0.90–2.82); P value for difference = 0.006] and for high-grade colitis [(RR 22.5; 95% CI, 6.37–79.4) vs. (RR 2.47; 95% CI, 0.90–6.72); P value for difference = 0.021]. We did not find differences in the relative risk between PD-1/PD-L1 inhibitors versus CTLA-4 for all-grade or high-grade liver

### Table 1. List of clinical trials included in the meta-analysis

<table>
<thead>
<tr>
<th>Reference</th>
<th>Ph</th>
<th>Tumor Type</th>
<th>No.</th>
<th>Treatment arms</th>
<th>Colitis</th>
<th>Increased AST</th>
<th>Rash</th>
<th>Hypothyroidism</th>
<th>Pneumonitis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>All Grade</td>
<td>All High</td>
<td>All Grade</td>
<td>All High</td>
<td>All Grade</td>
</tr>
<tr>
<td>Ipiilimumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Beer et al. 2016 (1)</td>
<td>3</td>
<td>Prostate</td>
<td>602</td>
<td>Ipiilimumab</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>2 Reck et al. 2016 (2)</td>
<td>3</td>
<td>SCLC</td>
<td>132</td>
<td>VP16 + Plt con Ipi</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>3 Eggermont et al. 2016 (3)</td>
<td>3</td>
<td>Melanoma</td>
<td>951</td>
<td>Ipiilimumab</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>4 Kwon et al. 2014 (4)</td>
<td>3</td>
<td>Prostate</td>
<td>799</td>
<td>Ipiilimumab</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>5 Reck et al. 2013 (5)</td>
<td>2</td>
<td>SCLC</td>
<td>130</td>
<td>CP</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>6 Lynch et al. 2012 (6)</td>
<td>2</td>
<td>NSCLC</td>
<td>204</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>7 Robert et al. 2011 (7)</td>
<td>3</td>
<td>Melanoma</td>
<td>502</td>
<td>Ipi + DTIC</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>8 Hodi et al. 2010 (8)</td>
<td>3</td>
<td>Melanoma</td>
<td>676</td>
<td>Ipi + Gp100</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Nivolumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 Ferris et al. 2016 (9)</td>
<td>3</td>
<td>Head and Neck</td>
<td>361</td>
<td>Nivolumab</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>10 Robert et al. 2015 (10)</td>
<td>3</td>
<td>Melanoma</td>
<td>518</td>
<td>Nivolumab</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>31</td>
</tr>
<tr>
<td>11 Weber et al. 2015 (11)</td>
<td>3</td>
<td>Melanoma</td>
<td>405</td>
<td>Nivolumab</td>
<td>5</td>
<td>2</td>
<td>12</td>
<td>1</td>
<td>35</td>
</tr>
<tr>
<td>12 Brahmer et al. 2015 (12)</td>
<td>3</td>
<td>NSCLC</td>
<td>272</td>
<td>Nivolumab</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>13 Borghaei et al. 2015 (13)</td>
<td>3</td>
<td>NSCLC</td>
<td>582</td>
<td>Nivolumab</td>
<td>2</td>
<td>1</td>
<td>9</td>
<td>1</td>
<td>36</td>
</tr>
<tr>
<td>14 Motzer et al. 2015 (14)</td>
<td>3</td>
<td>RCC</td>
<td>821</td>
<td>Nivolumab</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15 Herbst et al. 2016 (15)</td>
<td>3</td>
<td>NSCLC</td>
<td>1034</td>
<td>Pembrol 2 mg</td>
<td>4</td>
<td>3</td>
<td>10</td>
<td>2</td>
<td>29</td>
</tr>
<tr>
<td>16 Langer et al. 2016 (16)</td>
<td>2</td>
<td>NSCLC</td>
<td>123</td>
<td>Pembrol 10 mg</td>
<td>2</td>
<td>1</td>
<td>7</td>
<td>0</td>
<td>44</td>
</tr>
<tr>
<td>17 Reck et al. 2016 (17)</td>
<td>3</td>
<td>NSCLC</td>
<td>305</td>
<td>Pembrolizumab</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>18 Ribas et al. 2015 (18)</td>
<td>2</td>
<td>Melanoma</td>
<td>540</td>
<td>Pembrol 2 mg</td>
<td>3</td>
<td>2</td>
<td>N/A</td>
<td>N/A</td>
<td>6</td>
</tr>
<tr>
<td>19 Bellmunt et al. 2016 (19)</td>
<td>3</td>
<td>Bladder</td>
<td>542</td>
<td>Pembrolizumab</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Atezolizumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 Fehrenbacher et al. 2016 (20)</td>
<td>2</td>
<td>NSCLC</td>
<td>287</td>
<td>Atezolizumab</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>21 Rittmeyer et al. 2016 (21)</td>
<td>3</td>
<td>NSCLC</td>
<td>1125</td>
<td>Atezolizumab</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Abbreviations: No.: number of patients; Tx: treatments; Mos: months; hypoT: hypothyroidism, CPMem: carboplatin/Pemetrexed; Pembro: Pembrolizumab; CP: carboplatin/paclitaxel; DTIC: Dacarbazine; gp100: Glycoprotein 100; VP16: etoposide; Plt: platinum salt Con: concurrent; Seq: sequential.

*Proportion of high-grade adverse events estimated from study’s band diagram.
Toxicities, hypothyroidism, or pneumonitis (Table 4). In other subgroup analyses stratified by type of control-arm (chemotherapy vs. biological therapy vs. placebo), and type of tumor (melanoma vs. lung vs. other tumors), only a few subgroups with increased risk in irAEs were found. These analyses were limited by the small number of events in each subgroup (Supplementary Tables S3 and S4).

Fatal immune-related adverse events

Out of 6,528 patients treated with an ICI, 42 fatal irAEs were reported, totaling 0.64% of patients treated with ICIs, but up to 59% of the total number of fatal AEAs recorded in these clinical trials. Ipilimumab-induced colitis was the most common cause of fatal irAE.

Discussion

The incidence of immune-related adverse events in trials of immune checkpoint inhibitors can be challenging to discern because some adverse events, such as colitis, may be caused by a nonimmune reaction to drugs or to disease progression. Moreover, the report of irAE in the literature seems suboptimal, because no standardized method has been published specifying clinical criteria for irAEs versus nonimmune AEAs (10). This prompted us to perform this meta-analysis evaluating the risk of selected key irAEs associated with single-agent administration of ipilimumab, nivolumab, pembrolizumab, or atezolizumab in cancer patients. In this comprehensive analysis, 11,454 patients from 21 randomized phase II and III trials were included. We focused on five adverse event categories and selected the most common irAE in each category in order to better understand and illustrate the spectrum of irAEs from ICIs. The incidence of irAEs is relatively low, but is clearly changing the patterns of care of patients treated with these novel therapies. This meta-analysis has shown that all five of the selected irAEs were more frequent with ICI than the comparator arms.

Immune-mediated hepatitis, which can initially present with abnormalities in the liver function tests, may also occur secondary to ICIs. Our analysis showed a slight rise in risk of all-grade and serious AST elevation. Additionally, the combination of ipilimumab and dacarbazine, a drug known to cause hepatic toxicity (8), was associated with higher risk of AST elevation than expected with either agent alone. This finding may be relevant, because of the growing interest in testing combinations of ICI with other drugs; hepatitis may therefore become an important challenge for trials using this strategy. Indeed, combinations of sunitinib or pazopanib with nivolumab in RCC and ipilimumab with BRAF inhibitors in melanoma have already been shown to be significantly hepatotoxic and have led to drug discontinuation (40, 41). The incidence of hypothyroidism and skin rash increased 7- and 2-fold, respectively, in patients treated with ICI compared with patients treated in the comparator arms. These infrequent irAEs may be perceived as minor AEs; however, careful assessment should be performed considering the potentially life-threatening complications of severe hypothyroidism or serious skin toxicities.

Furthermore, the combinations of different ICIs, or of an ICI with other drugs such as tyrosine kinase inhibitors, may exponentially increase these risks and their severity, as seen with hepatitis (42). Pneumonitis, which most commonly manifests as radiological ground glass opacities, was selected based on the potential risk of severity previously described (43). Noninfectious pneumonitis is the small number of events in each subgroup (Supplementary Tables S3 and S4).

Fatal immune-related adverse events

Out of 6,528 patients treated with an ICI, 42 fatal irAEs were reported, totaling 0.64% of patients treated with ICIs, but up to 59% of the total number of fatal AEAs recorded in these clinical trials. Ipilimumab-induced colitis was the most common cause of fatal irAE.

Discussion

The incidence of immune-related adverse events in trials of immune checkpoint inhibitors can be challenging to discern because some adverse events, such as colitis, may be caused by a nonimmune reaction to drugs or to disease progression. Moreover, the report of irAE in the literature seems suboptimal, because no standardized method has been published specifying clinical criteria for irAEs versus nonimmune AEAs (10). This prompted us to perform this meta-analysis evaluating the risk of selected key irAEs associated with single-agent administration of ipilimumab, nivolumab, pembrolizumab, or atezolizumab in cancer patients. In this comprehensive analysis, 11,454 patients from 21 randomized phase II and III trials were included. We focused on five adverse event categories and selected the most common irAE in each category in order to better understand and illustrate the spectrum of irAEs from ICIs. The incidence of irAEs is relatively low, but is clearly changing the patterns of care of patients treated with these novel therapies. This meta-analysis has shown that all five of the selected irAEs were more frequent with ICI than the comparator arms.

Immune-mediated hepatitis, which can initially present with abnormalities in the liver function tests, may also occur secondary to ICIs. Our analysis showed a slight rise in risk of all-grade and serious AST elevation. Additionally, the combination of ipilimumab and dacarbazine, a drug known to cause hepatic toxicity (8), was associated with higher risk of AST elevation than expected with either agent alone. This finding may be relevant, because of the growing interest in testing combinations of ICI with other drugs; hepatitis may therefore become an important challenge for trials using this strategy. Indeed, combinations of sunitinib or pazopanib with nivolumab in RCC and ipilimumab with BRAF inhibitors in melanoma have already been shown to be significantly hepatotoxic and have led to drug discontinuation (40, 41). The incidence of hypothyroidism and skin rash increased 7- and 2-fold, respectively, in patients treated with ICI compared with patients treated in the comparator arms. These infrequent irAEs may be perceived as minor AEs; however, careful assessment should be performed considering the potentially life-threatening complications of severe hypothyroidism or serious skin toxicities.

Furthermore, the combinations of different ICIs, or of an ICI with other drugs such as tyrosine kinase inhibitors, may exponentially increase these risks and their severity, as seen with hepatitis (42). Pneumonitis, which most commonly manifests as radiological ground glass opacities, was selected based on the potential risk of severity previously described (43). Noninfectious pneumonitis is
a recognized specific adverse event associated with several drugs, such as rapalogs (everolimus or temsirolimus; ref. 44). It is also possible that in some situations, the control arm (e.g., everolimus) can also cause pneumonitis and could have diluted the overall relative risk of pneumonitis associated with ICIs. Nevertheless, immune-related pneumonitis can be one of the most common treatment-related events leading to treatment discontinuation (31). Despite the fact that several severe irAEs can occur in patients treated with anti–CTLA-4 and anti–PD-1/PD-L1 agents, treatment-related death remains a rare event. In our review, we found that fewer than 1% of all patients had ICI-related fatal events across all trials.

This meta-analysis has several limitations. First, coexisting conditions and classification of side effects as immune-related can be challenging (45). Also, we could not retrieve patient level data, and it therefore remains unknown whether cumulative, or combinations of several, immune-related toxicities may have played a role. Nevertheless, previous reports suggest that trial-level and patient-level meta-analyses reach comparable results (46). Many issues with ICI safety remain unresolved. Patients with discontinuation due to toxicity may have higher rate of response, but it is unclear whether the dosage of ICIs should be increased for patients without toxicity. Another intriguing question is whether the balance between safety and efficacy profile will be superior with immunotherapy combinations. For example, nivolumab combined with ipilimumab could improve progression-free survival, compared with ipilimumab alone, in patients with melanoma (47), but led to a rate of high-grade irAEs of 55%, compared with 27% or 14% for nivolumab or ipilimumab monotherapy, respectively. The development of biomarkers to improve patient selection may enhance the risk/benefit profile in patients with melanoma. For example, in melanoma patients whose tumors had PD-L1 expression < 5% by immunohistochemistry, combination therapy with nivolumab and ipilimumab significantly improved progression-free survival compared with nivolumab monotherapy. However, in patients whose tumors had PD-L1 expression in at least 5% of the cells, nivolumab alone had a favorable risk/benefit ratio, leading to less toxicity and similar progression-free survival than the combination arm (47).

This meta-analysis draws attention to a shift in toxicity patterns that oncologists will face in the coming years. Overall, the use of ICI is associated with an increased risk of developing all-grade irAEs in each category analyzed. These irAEs are generally well tolerated and increasingly recognized, but can occasionally be fatal, such as intestinal perforation secondary to colitis or high-grade hepatitis. Despite the increased relative risks of irAEs, these drugs are already achieving significant benefit in terms of quality of life and overall survival in several tumor types. The timely recognition and appropriate management of irAEs therefore becomes a priority.

Disclosure of Potential Conflicts of Interest
G. De Velasco is a consultant/advisory board member for Pfizer and Janssen. P.A. Ott is a consultant/advisory board member for BMS and Roche/Genentech. F.A. B. Schutz reports receiving speakers bureau honoraria from BMS, Pfizer, and Novartis and is a consultant/advisory board member for Novartis and Pfizer. G. Sonpavde reports receiving commercial research grants from Onyx, Bayer, Boehringer-Ingehelm, Celgene, Merck, Sanofi, and Pfizer; reports receiving speakers bureau honoraria from Clinical Care Options and Uptodate; is a consultant/advisory board member for Bayer, Sanofi, Argus, Agenys, Pfizer, Novartis, Eisa, Janssen, Amgen, AstraZeneca, Merck, and Genentech. F.S. Hodi reports receiving a commercial research grant from Bristol-Myers Squibb to institution, has ownership interest (including patents) in Bristol-Myers Squibb to institution per institutional policy, and is a consultant/advisory board member for Merck, Bristol-Myers Squibb, Roche, and AstraZeneca. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions
Conception and design: G. De Velasco, R.B. Moreira, F. Schutz, T.K. Choueiri
Development of methodology: G. De Velasco, T.K. Choueiri
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): G. De Velasco, D. Bosse, P.A. Ott, F.S. Hodi, T.K. Choueiri
Writing, review, and/or revision of the manuscript: G. De Velasco, Y. Je, D. Bosse, M.M. Awad, P.A. Ott, R.B. Moreira, F. Schutz, J. Bellmunt, G.P. Sonpavde, F.S. Hodi, T.K. Choueiri
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): G. De Velasco, D. Bosse, T.K. Choueiri
Study supervision: T.K. Choueiri

Grant Support
This study was supported in part by the Dana-Farber/Harvard Cancer Center Kidney Cancer Program, Dana-Farber/Harvard Cancer Center Kidney Cancer SPORE P50 CA161942-01, and The Trust family, Loker Pinard, and Michael Bingham Funds for Kidney Cancer Research (T.K. Choueiri).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 12, 2016; revised October 17, 2016; accepted February 23, 2017; published OnlineFirst February 28, 2017.


Correction: Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

The article by de Velasco and colleagues that was published in the April 2017 issue of Cancer Immunology Research (1) incorrectly reported the treatment arms of one clinical trial in Fig. 1 and Table 1. The corrected figure and table appear below. These changes do not alter the main conclusions of this study, nor do they affect the statistical analyses in the article, as the correct number of patients in each group (anti-PD-1/PD-L1 or anti-CTLA-4) was used in all instances. The authors regret these errors and thank Si-Cong Jiang, Fei-fei Zhang, and Jian-Jun Tang for their detection of them. The online version of the article has been updated to reflect the content of this correction.

Figure 1.
Table 1. List of clinical trials included in the meta-analysis

<table>
<thead>
<tr>
<th>Reference</th>
<th>Ph</th>
<th>Tumor type</th>
<th>No.</th>
<th>Treatment arms</th>
<th>Collitis</th>
<th>Increased AST</th>
<th>Rash</th>
<th>Hypothyroidism</th>
<th>Pneumonitis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Grade</td>
<td>Grade</td>
<td>Grade</td>
<td>Grade</td>
<td>Grade</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>All</td>
<td>High</td>
<td>All</td>
<td>High</td>
<td>All</td>
</tr>
<tr>
<td>Ipilimumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Beer et al. 2016 (1)</td>
<td>3 Prostate</td>
<td>602</td>
<td>Ipilimumab</td>
<td>Placebo</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>13 2</td>
</tr>
<tr>
<td>2 Beck et al. 2016 (2)</td>
<td>3 SCLC</td>
<td>1132</td>
<td>Ipilimumab + Plt</td>
<td>Placebo</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>14</td>
</tr>
<tr>
<td>3 Eggermont et al. 2016 (3)</td>
<td>3 Melanoma</td>
<td>951</td>
<td>Ipilimumab</td>
<td>Placebo</td>
<td>N/A</td>
<td>13 2</td>
<td>10</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>4 Kwon et al. 2014 (4)</td>
<td>3 Prostate</td>
<td>799</td>
<td>Ipilimumab</td>
<td>Placebo</td>
<td>2</td>
<td>24</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>5 Reck et al. 2013 (5)</td>
<td>2 SCLC</td>
<td>130</td>
<td>CP</td>
<td>Placebo</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>14</td>
</tr>
<tr>
<td>6 Lynch et al. 2012 (6)</td>
<td>3 Melanoma</td>
<td>502</td>
<td>Ipilimumab</td>
<td>Placebo</td>
<td>11</td>
<td>5</td>
<td>66</td>
<td>43</td>
<td>55</td>
</tr>
<tr>
<td>7 Robert et al. 2011 (7)</td>
<td>3 Melanoma</td>
<td>676</td>
<td>Ipilimumab</td>
<td>Placebo</td>
<td>21</td>
<td>12</td>
<td>4</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>8 Hodi et al. 2010 (8)</td>
<td>3 Melanoma</td>
<td>502</td>
<td>Ipilimumab</td>
<td>Placebo</td>
<td>7</td>
<td>2</td>
<td>12</td>
<td>1</td>
<td>15</td>
</tr>
<tr>
<td>Nivolumab</td>
<td>9 Ferris et al. 2016 (9)</td>
<td>3 Head and Neck</td>
<td>361</td>
<td>Nivolumab</td>
<td>Placebo</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>10 Robert et al. 2015 (10)</td>
<td>3 Melanoma</td>
<td>518</td>
<td>Nivolumab</td>
<td>Placebo</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>31</td>
</tr>
<tr>
<td>11 Weir et al. 2015 (11)</td>
<td>3 Melanoma</td>
<td>405</td>
<td>Nivolumab</td>
<td>Placebo</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>12 Brahmer et al. 2015 (12)</td>
<td>3 NSCLC</td>
<td>272</td>
<td>Nivolumab</td>
<td>Placebo</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>13 Borgen et al. 2015 (13)</td>
<td>3 NSCLC</td>
<td>582</td>
<td>Nivolumab</td>
<td>Placebo</td>
<td>2</td>
<td>1</td>
<td>9</td>
<td>1</td>
<td>36</td>
</tr>
<tr>
<td>14 Motzer et al. 2015 (14)</td>
<td>3 RCC</td>
<td>821</td>
<td>Nivolumab</td>
<td>Placebo</td>
<td>0</td>
<td>0</td>
<td>8</td>
<td>1</td>
<td>12</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>15 Herbst et al. 2016 (15)</td>
<td>3 NSCLC</td>
<td>1034</td>
<td>Pembro 2 mg</td>
<td>Placebo</td>
<td>3</td>
<td>3</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>16 Langer et al. 2016 (16)</td>
<td>2 NSCLC</td>
<td>123</td>
<td>CPem + con/seq Pembrolizumab</td>
<td>CPem</td>
<td>N/A</td>
<td>N/A</td>
<td>11</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>17 Reck et al. 2016 (17)</td>
<td>3 NSCLC</td>
<td>305</td>
<td>Pembrolizumab</td>
<td>Placebo</td>
<td>3</td>
<td>2</td>
<td>N/A</td>
<td>N/A</td>
<td>6</td>
</tr>
<tr>
<td>18 Ribas et al. 2015 (18)</td>
<td>2 Melanoma</td>
<td>540</td>
<td>Pembrolizumab</td>
<td>Placebo</td>
<td>2</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
<td>21</td>
</tr>
<tr>
<td>19 Bellmunt et al. 2016 (19)</td>
<td>3 Bladder</td>
<td>542</td>
<td>Pembrolizumab</td>
<td>Placebo</td>
<td>6</td>
<td>3*</td>
<td>N/A</td>
<td>N/A</td>
<td>2</td>
</tr>
<tr>
<td>Atezolizumab</td>
<td>20 Fehrenbacher et al. 2016 (20)</td>
<td>2 NSCLC</td>
<td>287</td>
<td>Atezolizumab</td>
<td>Placebo</td>
<td>2</td>
<td>1</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>21 Rittmeier et al. 2016 (21)</td>
<td>3 NSCLC</td>
<td>1125</td>
<td>Atezolizumab</td>
<td>Placebo</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
<td>0</td>
</tr>
</tbody>
</table>

Remarks:
- Abbreviations: Con, concurrent; CP, carboplatin/paclitaxel; CPem, carboplatin/pemetrexed; DTIC, dacarbazine; gp100, glycoprotein 100; hypoT, hypothyroidism; Mos, months; No., number of patients; Pembro, pembrolizumab; Plt, platinum salt; Seq, sequential; Tx, treatments; VP16, etoposide.
- *Proportion of high-grade adverse events estimated from study’s band diagram.

Reference

Published first March 20, 2018.
doi:10.1158/2326-6066.CIR-18-0078
©2018 American Association for Cancer Research.
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

Guillermo De Velasco, Youjin Je, Dominick Bossé, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/2326-6066.CIR-16-0237

Supplementary Material
Access the most recent supplemental material at:
http://cancerimmunolres.aacrjournals.org/content/suppl/2017/02/28/2326-6066.CIR-16-0237.DC1

Cited articles
This article cites 43 articles, 2 of which you can access for free at:
http://cancerimmunolres.aacrjournals.org/content/5/4/312.full#ref-list-1

Citing articles
This article has been cited by 20 HighWire-hosted articles. Access the articles at:
http://cancerimmunolres.aacrjournals.org/content/5/4/312.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerimmunolres.aacrjournals.org/content/5/4/312.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.